Cargando…
Investigation of the Selectivity of L-Type Voltage-Gated Calcium Channels 1.3 for Pyrimidine-2,4,6-Triones Derivatives Based on Molecular Dynamics Simulation
Human Ca(v)1.3 (hCa(v)1.3) is of great interest as a potential target for Parkinson’s disease. However, common medications like dihydropyridines (DHPs), a kind of classic calcium channel blocker, have poor selectivity to hCa(v)1.3 in clinical treatment, mainly due to being implicated in cardiovascul...
Autores principales: | Ye, Qi, Zhang, Zhenyu, Zhang, Wenying, Ding, Yushan, Zhao, Fan, Zhang, Jinghai, Song, Yongbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699898/ https://www.ncbi.nlm.nih.gov/pubmed/33233858 http://dx.doi.org/10.3390/molecules25225440 |
Ejemplares similares
-
Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca(2+) channel activators
por: Ortner, Nadine J., et al.
Publicado: (2014) -
Syntheses of Radioiodinated Pyrimidine-2,4,6-Triones as Potential Agents for Non-Invasive Imaging of Matrix Metalloproteinases
por: Breyholz, Hans-Jörg, et al.
Publicado: (2017) -
1,3-Dimethyl-5-(2-methylbenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione
por: Panchatcharam, R., et al.
Publicado: (2009) -
β subunits of voltage-gated calcium channels in cardiovascular diseases
por: Loh, Kelvin Wei Zhern, et al.
Publicado: (2023) -
5-[1-(1,3-Dimethyl-2,4,6-trioxohexahydropyrimidin-5-yl)-2-oxopropyl]-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione
por: Sweidan, Kamal, et al.
Publicado: (2013)